"Cytochrome P-450 CYP2A6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme that has specificity for the 7-hydroxylation of coumarin.
| Descriptor ID |
D065637
|
| MeSH Number(s) |
D08.244.453.491.250 D08.811.682.690.708.170.450.250 D12.776.422.220.453.491.250
|
| Concept/Terms |
Cytochrome P-450 CYP2A6- Cytochrome P-450 CYP2A6
- Cytochrome P 450 CYP2A6
- Cytochrome P450 CYP2A6
- P450 CYP2A6, Cytochrome
- Coumarin Hydroxylase
- Cytochrome P450, Family 2, Subfamily A, Polypeptide 6
- Cytochrome P-450 CYP-2A3
- Cytochrome P 450 CYP 2A3
- Coumarin 7-Hydroxylase
- Coumarin 7 Hydroxylase
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2A6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2A6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2A6" by people in this website by year, and whether "Cytochrome P-450 CYP2A6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2A6" by people in Profiles.
-
CYP2A6 Activity and Cigarette Consumption Interact in Smoking-Related Lung Cancer Susceptibility. Cancer Res. 2024 02 15; 84(4):616-625.
-
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations. Clin Pharmacol Ther. 2024 03; 115(3):576-594.
-
Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. Pharmacogenet Genomics. 2022 06 01; 32(4):159-172.
-
Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. Nicotine Tob Res. 2020 May 26; 22(6):910-918.
-
Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. Pharmacogenet Genomics. 2018 Jan; 28(1):7-16.
-
Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. Addiction. 2018 03; 113(3):509-523.
-
Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. Cancer Res. 2016 10 01; 76(19):5768-5776.
-
Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. Pharmacol Biochem Behav. 2016 09; 148:1-7.
-
CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations. Carcinogenesis. 2015 Jan; 36(1):99-103.
-
Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev. 2014 Sep; 23(9):1773-82.